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Abstract 
Background: Acute myeloid leukemias (AML) 
affect preferentially adults. Clinical manifestations 
are due to cytopenias and tissue infiltration. 
Manifestations vary with certain subtypes e.g. 
bleeding and infections are common with AML-M3, 
tissue infiltration is more often seen in AML-4 and 
M5, and bone marrow fibrosis is seen in AML-M7. 
Objective: To study demographic features and 
clinical manifestations of acute myeloid leukemia.  
Patients & Methods: A cross-sectional study was 
conducted at department of Pathology, Pakistan 
Institute of Medical sciences, Islamabad from July 
2007 to July 2009. All the cases of AML (diagnosed on 
bone marrow biopsy) belonging to all age groups 
and both sexes were included in the study. Age at 
diagnosis, symptoms and clinical findings in AML 
and its various subtypes were noted. Results were 
entered on SPSS version 14 for statistical analysis. 
Results: In a total of 82 cases of AML, 55% were 
males and 45% females, with mean age of 27.5+19.9 
years SD. The most common subtype was AML-M1 
(33%) followed by M3 (22%) and M4 (18%), 
respectively. The common presenting symptoms 
were pallor, fever and bleeding. Hepatomegaly, 
splenomegaly, lymphadenopathy and gum 
hyperplasia were also frequent. Tissue infiltration 
was the commonest in AML-M5 and M4. 
Conclusion: Acute myeloid leukemia is the 
malignancy of adults; it is more common in males 
and manifestations vary with its subtype.  
Key words: Leukemia, clinical manifestations, 
AML, hematological malignancies 
 
Introduction 
Acute leukemias are highly malignant neoplasms and are 
responsible for a large number of cancer-related deaths.1 
Although the survival rates have improved remarkably in the 
younger age group, the prognosis in older patients is still 
poor. 2  
Acute myeloid leukemia is characterized by hemopoietic 
insufficiency (with or without leukocytosis) and infiltration 
of bone marrow and other tissues by myeloid cells.  It is 
further classified into 8 subtypes. AML occurs at any age 
but is more common in adults (comprising about 80% of 
acute leukemias).  
Symptoms related to AML are caused by replacement of 
bone marrow and failure of normal hemopoiesis, resulting in 
anemia, bleeding and increased risk of infections. These 
may be general or related to specific organ system. The most 
common complaint is nonspecific fatigue or malaise. Fever 
is common and is the presenting feature in 15-20% patients. 
Bleeding can occur from nose, gums, gastrointestinal tract 
or urinary tract, or more commonly as petechial rash or easy 
bruisibility. The severity correlates with degree of 
thrombocytopenia or presence of disseminated intravascular 
coagulation (DIC), most commonly observed in AML-M3.  
Bone pains occur in less than 20% of patients.3 Leukemic 
blast cells circulate and infiltrate other tissues. 
Extramedullary involvement is the most common in 
monocytic and myelomonocytic leukemias and usually 
involves tissues like liver, spleen lymph nodes, gums, skin 
and CNS. Palpable splenomegaly and hepatomegaly occur 
in about one third of patients. 
Pustules or other major pyogenic infections of the skin and 
of minor cuts or wound common. With severe neutropenia 
after chemotherapy however, major bacterial, fungal or viral 
infections become frequent. Myeloid (granulocytic) sarcoma 
is an extra medullary tumor that occurs in 2 to 14% of cases 
of AML.3 The tumors are usually localized; they often 
involve bone, periosteum, soft tissues, lymph nodes, or skin. 
Common sites are orbit and paranasal sinuses, but other sites 
may be involved. Testicular infiltration is less common in 
AML than in ALL, with an incidence of 1 to 8%.4 
Meningeal disease has been reported to develop in 5 to 20% 
of children and up to 16% of adults with AML.3 The CNS 
disease is associated with young age (<2 years), 
hyperleukocytosis, and the AML-M0 variants.   
The diagnosis of acute leukemia is based primarily on well-
defined morphologic criteria and findings of cytochemical 
stains. Immunophenotyping is also very important 
particularly in characterizing morphologically poorly 
differentiated acute leukemias. Cytogenetics provide an 
important prognostic information and are becoming vitally 
important in classifying these leukemias (WHO 
Classification) and also determining the appropriate 
treatment protocol. Molecular studies are also helpful in 
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defining prognosis, response to treatment and identification 
of minimal residual disease.       
A number of clinical and biologic factors affect the outcome 
and response to treatment in AML patients. The chance of 
cure for a specific patient depends on a number of 
prognostic factors.5   In AML some differences in prognosis 
are seen among the different FAB categories. Cases of M5, 
M6, and M7 generally have a worse prognosis than those of 
M1-M4, and AML M0 has the worst prognosis. Cure rates 
for promyelocytic leukemia can be as high as 98%.6 
Conversely, evidence of maturation of leukemic cells, such 
as the presence of granules or auer rods, strong positivity of 
SBB and positive reactions for non-specific esterase, is 
associated with a more favorable prognosis. Other adverse 
prognostic factors include an age over 60 years,  poor 
performance score before treatment, AML resulting from 
prior chemotherapy or antecedent MDS, and a white-cell 
count of more than 20,000 per cubic millimeter or an 
elevated serum lactate dehydrogenase level at presentation. 
Patients with t15; 17, t8; 21, t16; 16, and inv 16 have good 
prognosis. Cure rates in clinical trials have ranged from 20–
45%.7   
The objective of this study was to look into demographic 
features and clinical manifestations of acute myeloid 
leukemia and its various subtypes. 
 
Patients & Methods 
This was a cross-sectional study conducted at the 
Department of Pathology, Pakistan Institute of Medical 
Sciences (PIMS), Islamabad, from July 2007- July 2009. 
Inclusion Criteria: All freshly diagnosed cases of 
Acute Myeloid Leukemia from all age groups and both 
sexes were included in the study. 
Exclusion Criteria: Patients already diagnosed as 
AML, and receiving cytotoxic therapy were excluded. 
A detailed clinical history of patients especially regarding 
age, sex, duration of symptoms, fever, pallor, bone pain, 
bleeding and other constitutional symptoms were entered in 
specially designed performa. Physical examination was also 
performed especially pertaining to lymphadenopathy, 
hepatomegaly, splenomegaly, purpuric or petechial rash and 
gum hyperplasia etc.  
In every patient, about 2.5 ml blood sample was collected in 
EDTA containing tube. Complete blood picture was done on 
an automated hematology analyzer, Sysmex Kx-21. 
Peripheral blood smears were freshly made and stained by 
Wright stain and two slides were made for reticulocyte 
count by brilliant cresyl blue. 
All the patients were subjected to bone marrow aspirations 
using disposable lumbar puncture needle size 16g. Bone 
marrow smears were stained by Wright stain. In all cases 
cytochemical stains (Sudan Black B, Non-specific esterase 
and PAS) were performed, according to requirement. 
Statistical Analysis: All the findings (including clinical 
features, peripheral film and bone marrow findings) were 
entered on SPSS version 14 for final analysis.  
 
Results 
In a total of 82 patients of AML belonging to all age groups, 
45 (55%) were males and 37(45%) were females with male 
to female ratio of 1.2:1. Age ranged from 2 months to 79 
years with a mean age of 27.5 + 19.92 SD years. Among 
them 26 (38%) were below the age of 15 years and 56 (68 
%) were more than 15 years with adult to children ratio of 
2.2:1.  
 
Table1: Frequency of AML Subtypes (N= 82) 
Subtype N (%) 
AML-M1 
AML-M2 
AML-M3 
AML-M4 
AML-M5 
AML-M6 
AML-M7 
AML-M0 
27 (33) 
12 (15) 
18 (22) 
15 (18) 
06 (7.2) 
02 (2.4) 
01 (1.2) 
01 (1.2) 
 
`Table 2: Clinical Features in AML 
Clinical Feature  N (%) 
Pallor 71 (86.6) 
Bleeding 43 (52.4) 
Fever 68 (82.9) 
Weakness 31 (38) 
Palpitation 02 (2.4) 
Weight loss 08 (9.8) 
Bone pains 15 (18.3) 
The most common subtype (Table 1) was AML-M1 (33%) 
followed by AML-M3 (22%), AML-M4 (18%), AML-M2 
(14.6%) and AML-M5 (7.3%). AML-M0, M6 and M7 were 
relatively infrequent. 
Table 3: Physical Findings in AML Subtypes 
Physical finding 
AML-M1 
N:27 
N (%) 
AMLM2 
N:12 
N (%) 
AML-M3 
N:18 
N (%) 
AML-M4 
N:15 
N (%) 
AML-M5 
N:06 
N (%) 
Pallor 24 (89) 10 (83.3) 14 (77.8) 13 (86.7) 06(100) 
Lymphadenopathy 06 (29.6) 04(32.3) 05 (28) 06 (40) 05 (83.3) 
Hepatomegaly 16 (59.3) 04 (13.3) 05 (27.8) 07(46.7) 06(100) 
Splenomegaly 14 (52) 05 (41.7) 05 (27.8) 07(46.7) 05 (83.3) 
Gum Hyperplasia 0 (00) 0(00) 01(5.6) 03 (20) 03 (50) 
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The most common presenting symptoms were pallor, fever 
and bleeding seen in 87%, 83% and 52.4% patients, 
respectively (Table 2). Other symptoms which were 
observed less frequently were weight loss (9.8%), weakness 
(38%), dyspnea (12.2%), easy fatigability (29%) and 
palpitation (2.4%). Bone pains were noted in 18.3% 
patients. 
Among the physical findings pallor was the most frequent 
(87%). Hepatomegaly, splenomegaly, lymphadenopathy and 
gum hyperplasia were observed in 48%, 45%, 38% and 
9.8% cases respectively. Hepatosplenomegaly in majority of 
cases was mild to moderate type.  
As shown in Table 3, hepatosplenomegaly was the 
commonest in AML-M5, M4 and M1. Gum hyperplasia was 
most frequent in AML-M4 and M5 (3 cases each). These 
findings show that tissue infiltration was most common in 
AML-M5 and M4 and least frequent in patients of AML-
M3. 
 
Discussion 
AML accounts for approximately 25% of all leukemias in 
adults in the western world, and therefore is the most 
frequent form of leukemia in this age group. 8   In the 
present study among the total of 82 patients belonging to all 
age groups, male to female ratio was 1.2:1.The same 
frequency of gender distribution has also been reported in 
different international and local studies, e.g. 1.5:1.  1.2:1 
and 1.7:1. 9-11 However one of the studies done by Frederick 
R. et al (to look for changes in biological features with age) 
shows an equal distribution of AML in both males and 
females.  A study done by Kumar L et al on clinico- 
morphological features of AML shows male to female ratio 
of 2:1. 12  
AML is primarily a disease of adults. Overall incidence of 
AML increases with age. 13   Patients newly diagnosed with 
AML have a median age of 65 years. 14 In our study the 
mean age was quite low i.e. 27.5 + 19.92 SD years. These 
results are comparable with another local study done at 
Agha Khan University hospital Karachi to see the frequency 
of AML subtypes in their population and they found that the 
mean age of their patients was 32 years (ranging between 6 
months to 85 years). 9  In a study done by Hassan et al in 
1993 on FAB subtypes and clinico-hematological features of 
AML the mean age was different for different FAB 
subtypes; For example they found that  the mean age of M1, 
M2, M3 and M5 cases was between 25 and 29 years, 
whereas in M4 patients it was 45.6 years. 15  Almost similar 
observations were also made in our study. In a study done at 
Armed Forces Bone Marrow Transplant Centre, to evaluate 
outcome of treatment on patients of patients of denovo 
AML, the median age of patients was 21 years (ranging 
from 7 to 56 years).11  
The median age for AML is quite high in West as compared 
to our studies. In one of the studies done in U.K. on AML 
patients from 26 hospitals in south and west region, the 
median age was 67 years. 16 In another study done in Spain 
on cytogenetic abnormalities of AML, median age was 61 
years. (range was between 1 month-94 years) 17   Reports 
from Japan and Australia show a mean age of 51 and 52 
years, respectively.18 The reasons for the difference between 
age at presentation in subjects from the various regions are 
not clear. Whether this represents a true geographic/ethnic 
difference is difficult to ascertain. But higher mean age in 
the West is probably due to overall higher mean age in these 
countries as compared to East.  
Disrupted hematopoiesis leads to the most common 
presenting manifestations, i.e. anemia, infection, and 
bleeding tendency.  Among our patients majority presented 
with pallor and fever.  Bleeding was also a common 
presenting feature. Bleeding however was a prominent 
symptom in AML-M3. Most common types of bleeding 
were epistaxis, gum bleeding and easy bruisibility.  In 
AML-M3, there is also risk of bleeding from other sites and 
the bleeding diathesis is either due to thrombocytopenia 
alone or as a part of DIC. 
Other features included weakness, easy fatigability, dysnea, 
palpitation, bone pains and weight loss.  Similar findings 
have been reported in different studies. 12,19-21  In one of the 
local studies done by Qazi et al on bleeding diathesis in 
acute myeloid leukemia it was noted that DIC was the most 
frequent in AML M3 (69 %), followed by in M5 (40 %), M2 
(23.1 %), M4 (18.2 %) and M1 (16.6 %), respectively. 22 
Ghosh et al from Tata Memorial hospital reported that 
majority of their patients presented with fatigue and pallor. 
They also reported that bleeding was most commonly seen 
in acute promyelocytic leukemia and monocytic leukemia. 23  
Hepatomegaly and splenomegaly were observed in 48% and 
45% patients respectively in our study. Majority had mild to 
moderate hepatosplenomegaly. Lymph node enlargement 
was noted in 38% patients. Gum hyperplasia was seen 
inonly 10% cases and majority of them belonged to FAB 
types M4 and M5. Almost similar observations were made 
by Kumar et al in 2004 (42% patients and comparatively 
lesser number of patients having splenomegaly or 
lymphadenopathy, however gum hypertrophy was noted in 
24% patients compared to 10% in our study. 12 Another 
interesting point which should be noted regarding this study 
is that majority of their patients with tissue infiltration 
belonged to AML-M4, M5 and M1 subtypes, the finding 
comparable to our results. Hoffman has reported the 
presence of splenomegaly in 50% of his cases. 24 In another 
study done by Ghosh et al, hepatosplenomegaly in 68 
patients (26.2%) and lymphadenopathy was seen in 36% 
patients.23 Two patients with acute myelomonocytic 
leukemia presented with extramedullary leukemia. Both 
these patients presented with orbital masses and belonged to 
the pediatric age group. We also had one patient with 
testicular swelling (he was a case of AML-M5) and the 
other one with bilateral proptosis.  Similarly one of our 
patients presented with testicular swelling and when we 
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looked into the frequency of these findings in AML 
subtypes it was noticed that hepatosplenomegaly, 
lymphadenopathy and gum hyperplasia was most frequent in 
AML4, M5. Tissue infiltration is seen more with monocytic 
and myelomonocytic leukemia than with other subtypes of 
AML. Boils and mouth ulcers were seen in 6 patients. 
Geographic variations have been reported in the distribution 
of extramedullary leukemia and are more frequently 
reported from the African countries such as Uganda, Egypt 
and Turkey. Acute myeloblastic leukemia is the malignancy 
of adults and depending upon its subtype has variable 
manifestations.  
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